We have confirmed that MYL9 can reduce the secretion of CCL2 and TGF-β1 by CAFs, while CCL2 combined with TGF-β1 can promote the proliferation, migration, and invasion of CRC cells. The gene discussed is MYL9; the disease is colorectal carcinoma.